Open an account

ConvaTec Group

CNVVF · LONDON

$3.32+$0.145 (+4.57%)TodayMarket closed ·
No price history for this range.

About CNVVF

ConvaTec Group Plc operates as holding company, which engages in medical business. The firm is engaged in the development, manufacture and sale of medical products, services, and technologies. The company is focused on solutions for the management of chronic conditions. The company markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Advanced Wound Care includes advanced dressings for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories, and personalized services for individuals with a stoma. Continence Care includes products and services for people with urinary continence issues related to spinal cord injuries and other causes. Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.

Employees
10,903
Headquarters
London, Berkshire
Listed
Oct 26, 2016
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
convatecgroup.com

CNVVF key statistics

Market cap
4.50B
Price-earnings ratio
0.00
Dividend yield
2.38%
Average volume
1.94K
Volume
667
Open price
$3.32
High today
$3.32
Low today
$3.32
52 Week high
$3.65
52 Week low
$2.30

ConvaTec Group (CNVVF) at a glance

ConvaTec Group (CNVVF) last traded at $3.32, with a market cap of 4.50B, a price-to-earnings ratio of 0.00 and a dividend yield of 2.38%.

Volume so far is 667 shares, below the average of 1.94K shares a day.

Over the past year ConvaTec Group has ranged from $2.30 to $3.65, and now sits 76% of the way up that range.

ConvaTec Group met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.085 per share against an estimate of $0.0862.

CNVVF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 7.2% on average.

  1. Q2 FY22: reported $0.065 per share against an estimate of $0.0727
  2. Q4 FY22: reported $0.065 per share against an estimate of $0.0601
  3. Q2 FY23: reported $0.068 per share against an estimate of $0.0606
  4. Q4 FY23: reported $0.066 per share against an estimate of $0.0631
  5. Q4 FY24: reported $0.084 per share against an estimate of $0.0808
  6. Q2 FY25: reported $0.08 per share against an estimate of $0.0803
  7. Q4 FY25: reported $0.096 per share against an estimate of $0.101
  8. Q2 FY26: reported $0.085 per share against an estimate of $0.0862

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.